Related references
Note: Only part of the references are listed.Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods
Fatma Hanci et al.
CEPHALALGIA (2021)
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
Messoud Ashina et al.
CEPHALALGIA (2021)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
PACAP27 induces migraine-like attacks in migraine patients
Hashmat Ghanizada et al.
CEPHALALGIA (2020)
Cryo-EM structures of PAC1 receptor reveal ligand binding mechanism
Jia Wang et al.
CELL RESEARCH (2020)
PAC1receptor blockade reduces central nociceptive activity: new approach for primary headache?
Jan Hoffmann et al.
PAIN (2020)
Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers
Lanfranco Pellesi et al.
CEPHALALGIA (2020)
Agonist bias and agonist-dependent antagonism at corticotrophin releasing factor receptors
Zoe Tasma et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review
Cecilia Rustichelli et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Antagonism of CGRP Signaling by Rimegepant at Two Receptors
Kylie S. Pan et al.
FRONTIERS IN PHARMACOLOGY (2020)
Combinatorial expression of GPCR isoforms affects signalling and drug responses
Maria Marti-Solano et al.
NATURE (2020)
Multiplexed analysis of the secretin-like GPCR-RAMP interactome
Emily Lorenzen et al.
SCIENCE ADVANCES (2019)
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide
Cristina Moldovan Loomis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured
Christopher S. Walker et al.
CEPHALALGIA (2018)
Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin
Rebekah L. Bower et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2018)
G Protein-Coupled Receptor Endosomal Signaling and Regulation of Neuronal Excitability and Stress Responses: Signaling Options and Lessons From the PAC1 Receptor
Victor May et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Receptor activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide and adrenomedullin receptors to Gs
Michael J. Woolley et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Lost in Translation: CRFI Receptor Antagonists and Addiction Treatment
Yavin Shaham et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Vasoactive Intestinal Peptide modulates trophoblast-derived cell line function and interaction with phagocytic cells through autocrine pathways
Daiana Vota et al.
SCIENTIFIC REPORTS (2016)
A second trigeminal CGRP receptor: function and expression of the AMY1 receptor
Christopher S. Walker et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38
Faisal Mohammad Amin et al.
BRAIN (2014)
PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells
C. S. Walker et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Quantification of Ligand Bias for Clinically Relevant β2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy
Emma T. van der Westhuizen et al.
MOLECULAR PHARMACOLOGY (2014)
New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2
Terry Kenakin
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function
D. Wootten et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients
Bernadett Tuka et al.
CEPHALALGIA (2013)
PACAP induces the dimerization of PAC1 on the nucleus associated with the cAMP increase in the nucleus
Rongjie Yu et al.
NEUROSCIENCE LETTERS (2013)
Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity
Janna Blechman et al.
Frontiers in Endocrinology (2013)
Consequences of splice variation on Secretin family G protein-coupled receptor function
Sebastian G. B. Furness et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1
Anthony J. Harmar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Tommy Seaborn et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)/PAC1HOP1 Receptor Activation Coordinates Multiple Neurotrophic Signaling Pathways Akt ACTIVATION THROUGH PHOSPHATIDYLINOSITOL 3-KINASE γ AND VESICLE ENDOCYTOSIS FOR NEURONAL SURVIVAL
Victor May et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes
Nicola J. Smith et al.
PHARMACOLOGICAL REVIEWS (2010)
PACAP38 induces migraine-like attacks in patients with migraine without aura
Henrik Winther Schytz et al.
BRAIN (2009)
Alternative splicing of G protein-coupled receptors: physiology and pathophysiology
Danijela Markovic et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine
A. Rahmann et al.
CEPHALALGIA (2008)
PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases
T. K. Monaghan et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Why the Schild method is better than Schild realised
David Colquhoun
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Katie Leach et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
G protein-coupled receptor dimerisation: Molecular basis and relevance to function
Graeme Milligan
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2007)
Determining the potency and molecular mechanism of action of insurmountable antagonists
Terry Kenakin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
New concepts in drug discovery: Collateral efficacy and permissive antagonism
T Kenakin
NATURE REVIEWS DRUG DISCOVERY (2005)
Novel receptor partners and function of receptor activity-modifying proteins
A Christopoulos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Expression of VPAC2 receptor and PAC1 receptor splice variants in the trigeminal ganglion of the adult rat
P Chaudhary et al.
MOLECULAR BRAIN RESEARCH (2002)
Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptides stimulate mitogen-activated protein kinase in the pituitary cell line GH4C1 by a 3′,5′-cyclic adenosine monophosphate pathway
C Le Péchon-Vallée et al.
NEUROENDOCRINOLOGY (2000)
Share Paper
